These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 1017726)

  • 1. Treatment of thrombosis by sequential therapy with ancrod followed by streptokinase. Clinical pharmacology and rheology.
    Forbes CD; Barbenell J; Prentice CR
    Haemostasis; 1976; 5(6):348-54. PubMed ID: 1017726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SDS polyacrylamide gel characterization of serum FDP produced in response to ancrod and streptokinase/plasminogen infusion in man.
    Lane DA; Robbins A; Rampling MW; Kakkar VV
    Br J Haematol; 1977 May; 36(1):137-48. PubMed ID: 871418
    [No Abstract]   [Full Text] [Related]  

  • 3. Controlled trial of the sequential use of streptokinase and ancrod in the treatment of deep vein thrombosis of lower limb.
    Tibbutt DA; Chesterman CN; Williams EW; Faulkner T; Sharp AA
    Thromb Haemost; 1977 Apr; 37(2):222-32. PubMed ID: 577626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The fibrinolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products.
    Prentice CR; Hampton KK; Grant PJ; Nelson SR; Nieuwenhuizen W; Gaffney PJ
    Br J Haematol; 1993 Feb; 83(2):276-81. PubMed ID: 8457476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible pathway for formation of fibrin degradation products during ancrod therapy.
    McKillop C; Edgar W; Forbes CD; Prentice CR
    Nature; 1975 Jun; 255(5510):638-40. PubMed ID: 1134556
    [No Abstract]   [Full Text] [Related]  

  • 6. Ancrod: clinical indications and methods of use.
    Wright JG; Geroulakos G
    Semin Vasc Surg; 1996 Dec; 9(4):315-28. PubMed ID: 8958608
    [No Abstract]   [Full Text] [Related]  

  • 7. Subcutaneous ancrod after operation for fractured hip--a dose-ranging and feasibility study.
    Lowe GD; Morrice JJ; Fulton A; Forbes CD; Prentice CR; Barbenel JC
    Thromb Haemost; 1978 Aug; 40(1):134-43. PubMed ID: 725844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo production of soluble complexes containing fibrinogen-fibrin related antigen during ancrod therapy.
    McKillop C; Edgar W; Forbes CD; Prentice CR
    Thromb Res; 1975 Sep; 7(3):361-72. PubMed ID: 1188838
    [No Abstract]   [Full Text] [Related]  

  • 9. Ancrod causes rapid thrombolysis in patients with acute stroke.
    Pollak VE; Glas-Greenwalt P; Olinger CP; Wadhwa NK; Myre SA
    Am J Med Sci; 1990 May; 299(5):319-25. PubMed ID: 2186630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of ancrod and heparin as anticoagulants following endarterectomy in the dog.
    Daniel TM; Pizzo SV; Mckee PA
    Ann Surg; 1976 Aug; 184(2):223-8. PubMed ID: 952568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Streptokinase and reduced plasma viscosity: a second benefit.
    Moriarty AJ; Hughes R; Nelson SD; Balnave K
    Eur J Haematol; 1988 Jul; 41(1):25-36. PubMed ID: 3402584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinolysis in glomerulonephritis treated with ancrod: renal functional, immunologic and histopathologic effects.
    Kim S; Wadhwa NK; Kant KS; Pollak VE; Glas-Greenwalt P; Weiss MA; Hong CG
    Q J Med; 1988 Nov; 69(259):879-905. PubMed ID: 3078212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase.
    Theiss W; Asbeck F; Kriessmann A; Trübestein G; Knoch K; de Swart CA; Marbert GA; van de Loo JC
    Thromb Haemost; 1983 Oct; 50(3):664-8. PubMed ID: 6196852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biologic data furnished by the experience of thrombolytic treatments with streptokinase].
    Samama M; Yver J; Casubolo L; Soria J; Bousser J
    Nouv Rev Fr Hematol; 1968; 8(1):84-92. PubMed ID: 4232155
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic defibrinogenation by ancrod: effect on limb blood flow in peripheral vascular disease.
    Wiles PG; Nelson SR; Hampton KK; Casali B; Boothby M; Prentice CR
    Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):385-8. PubMed ID: 2133215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defibrinogenating enzymes.
    Bell WR
    Drugs; 1997; 54 Suppl 3():18-30; discussion 30-1. PubMed ID: 9360849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of streptokinase on fibrinogen and related proteins in plasma.
    Bowie LJ; Kinney R; Vye M; Eckert B; Kwaan HC
    Clin Chem; 1986 Jan; 32(1 Pt 1):67-70. PubMed ID: 3940737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A report on the use of Arvin in patients with pre-gangrene of the lower limb.
    Humphreys WV; Walker A; Charlesworth D
    Br J Surg; 1977 Jan; 64(1):31-3. PubMed ID: 831951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic effect of blood viscosity in stroke].
    Heiss WD
    Beitr Infusionther Klin Ernahr; 1981; 8():22-32. PubMed ID: 6172108
    [No Abstract]   [Full Text] [Related]  

  • 20. Ancrod: normalization of fibrinolytic enzyme abnormalities in patients with systemic lupus erythematosus and lupus nephritis.
    Glas-Greenwalt P; Kant KS; Dosekun A; Frazier J; Allen C; Pollak VE
    J Lab Clin Med; 1985 Jan; 105(1):99-107. PubMed ID: 3871465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.